IGC Pharma annual r&d spending
2018
2019
2020
2021
2022
2023
2024
2025
2025
IGC Pharma R&D Spending Growth & History (IGC)
IGC Pharma's r&d spending was $3.9M for fiscal 2025.
View full IGC Pharma company overviewIGC Pharma annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 · Dec 31 | 2025-12-31 | $3.9M | — | — |
| 2025 · Mar 31 | 2025-03-31 | $3.7M | −$118,000 | −3.13% |
| 2024 | 2024-03-31 | $3.8M | $312,000 | +9.01% |
| 2023 | 2023-03-31 | $3.5M | $1.1M | +48.54% |
| 2022 | 2022-03-31 | $2.3M | $1.4M | +150.81% |
| 2021 | 2021-03-31 | $929,000 | −$82,000 | −8.11% |
| 2020 | 2020-03-31 | $1.0M | −$245,000 | −19.51% |
| 2019 | 2019-03-31 | $1.3M | $1.1M | +816.79% |
| 2018 | 2018-03-31 | $137,000 | — | — |
IGC Pharma quarterly r&d spending
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 · Jun 30 | 2026-06-30 | $1.4M | $539,000 | +63.34% |
| Q1 2026 · Mar 31 | 2026-03-31 | $1.3M | $275,000 | +27.58% |
| Q4 2025 | 2025-12-31 | $485,000 | −$367,000 | −43.08% |
| Q2 2026 · Sep 30 | 2025-09-30 | $1.6M | $671,000 | +73.17% |
| Q1 2026 · Jun 30 | 2025-06-30 | $851,000 | −$38,000 | −4.27% |
| Q4 2025 | 2025-03-31 | $997,000 | $142,000 | +16.61% |
| Q3 2025 | 2024-12-31 | $852,000 | −$51,000 | −5.65% |
| Q2 2025 | 2024-09-30 | $917,000 | −$351,000 | −27.68% |
| Q1 2025 | 2024-06-30 | $889,000 | $142,000 | +19.01% |
| Q4 2024 | 2024-03-31 | $855,000 | $362,000 | +73.43% |
| Q3 2024 | 2023-12-31 | $903,000 | $97,000 | +12.03% |
| Q2 2024 | 2023-09-30 | $1.3M | $500,000 | +65.10% |
| Q1 2024 | 2023-06-30 | $747,000 | −$647,000 | −46.41% |
| Q4 2023 | 2023-03-31 | $493,000 | −$740,000 | −60.02% |
| Q3 2023 | 2022-12-31 | $806,000 | $429,000 | +113.79% |
| Q2 2023 | 2022-09-30 | $768,000 | $492,000 | +178.26% |
| Q1 2023 | 2022-06-30 | $1.4M | $950,000 | +213.96% |
| Q4 2022 | 2022-03-31 | $1.2M | $899,000 | +269.16% |
| Q3 2022 | 2021-12-31 | $377,000 | $223,000 | +144.81% |
| Q2 2022 | 2021-09-30 | $276,000 | $57,000 | +26.03% |
| Q1 2022 | 2021-06-30 | $444,000 | $222,000 | +100.00% |
| Q4 2021 | 2021-03-31 | $334,000 | $87,000 | +35.22% |
| Q3 2021 | 2020-12-31 | $154,000 | −$141,000 | −47.80% |
| Q2 2021 | 2020-09-30 | $219,000 | −$3,000 | −1.35% |
| Q1 2021 | 2020-06-30 | $222,000 | −$25,000 | −10.12% |
| Q4 2020 | 2020-03-31 | $247,000 | −$529,000 | −68.17% |
| Q3 2020 | 2019-12-31 | $295,000 | $129,000 | +77.71% |
| Q2 2020 | 2019-09-30 | $222,000 | −$56,000 | −20.14% |
| Q1 2020 | 2019-06-30 | $247,000 | $211,000 | +586.11% |
| Q4 2019 | 2019-03-31 | $776,000 | $773,538 | +31419.09% |
| Q3 2019 | 2018-12-31 | $166,000 | $166,000 | — |
| Q2 2019 | 2018-09-30 | $278,000 | $200,000 | +256.41% |
| Q1 2019 | 2018-06-30 | $36,000 | −$20,538 | −36.33% |
| Q4 2018 | 2018-03-31 | $2,462 | — | — |
| Q3 2018 | 2017-12-31 | $0 | — | — |
| Q2 2018 | 2017-09-30 | $78,000 | — | — |
| Q1 2018 | 2017-06-30 | $56,538 | — | — |
IGC Pharma r&d spending trends
Between the periods ended 2018-03-31 and 2025-12-31, IGC Pharma's r&d spending increased from $137,000 to $3.9M, a change of $3.8M. The latest reported quarter, Q2 2026 · Jun 30, shows $1.4M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review IGC Pharma source filings ↗